Deltasone (prednisone) is a corticosteroid. It prevents the release of substances that cause inflammation and also suppresses the immune system. The therapy is used to treat many conditions including allergic reactions, breathing difficulties, occasional symptoms of certain cancers, and relapse management in multiple sclerosis (MS).

Corticosteroids works in MS relapse management by closing the damaged blood-brain barrier and reducing inflammation in the central nervous system.

MS patients generally take a three- to five-day treatment of high dose intravenous corticosteroid followed by a gradual dose reduction via an oral corticosteroid (may last from 10 days to five or six weeks). Prednisone is usually the choice for this oral tapering off.

It may also be used orally if the corticosteroid for intravenous treatment is not desired or is contraindicated.

Prednisone should not be taken if a fungal infection is present. Because it weakens the immune system, people taking prednisone shouldn’t be around others who are sick or who have infections.

Some common side effects associated with prednisone include insomnia, mood changes, increased appetite, gradual weight gain, acne, increased sweating, skin problems, difficulties with healing wounds, headache, nausea and gastric disorders, and changes in the shape or location of body fat.

Other prednisone brands are Rayos, Sterapred, Sterapred DS, and Prednicot.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



Aubagio’s Long-term Benefits Not Influenced by Prior Treatments, Review Finds

Prior treatment with disease-modifying therapies (DMTs) does not affect the long-term benefits of Aubagio (teriflunomide) in treating relapsing forms of multiple sclerosis (MS), according to a review study. The study, “Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis,” was published in the journal BMC Neurology. Breakthrough disease activity, poor tolerability, […]

#MSVirtual2020 – Long-term Aubagio Use Seen to Lower Relapse Risk for Children

Continuous treatment with Aubagio (teriflunomide) can safely lower the risk of relapses and disability progression in children with relapsing forms of multiple sclerosis (MS), according to interim data from the open-label extension of a Phase 3 trial. These findings were detailed at MSVirtual2020 by Tanuja Chitnis, MD, an associate neurologist at Brigham and Women’s Hospital […]

#MSVirtual2020 – Low Rituximab Doses Are Safer, as Effective as Higher Ones

Low doses of rituximab, an anti-inflammatory medication used off-label to treat multiple sclerosis (MS), are safer and as effective as higher doses at reducing the frequency of relapses and the number of MS lesions, a clinical study shows. The study findings were presented at MSVirtual2020 by Luciana Midaglia, MD, a neurologist from the Multiple Sclerosis […]

Children with MS May Have More Relapses, But They Recover More Fully

Children with multiple sclerosis (MS) recover more quickly and “significantly better” from relapses than do adults — patients with disease onset at age 18 or older, researchers reported. The study, “Improved relapse recovery in paediatric compared to adult multiple sclerosis,” was published in the journal Brain. Relapses and incomplete relapse recovery contribute to increasing disability in […]

Ofatumumab Seen as Superior to Aubagio at Lowering Relapse Rates in Phase 3 Trials

Novartis‘ ofatumumab outperformed Aubagio (teriflunomide) at lowering the frequency of relapses and preventing disability progression among people with relapsing forms of multiple sclerosis (MS), a study based on clinical trial data reports. The study, “Ofatumumab versus Teriflunomide in Multiple Sclerosis,” was published in The New England Journal Of Medicine. Ofatumumab is an antibody therapy that works by targeting […]

B-Cells Infected by Epstein-Barr Virus Linked to MS Relapse Risk in Study

Immune B-cells that proliferate unchecked when infected by the Epstein-Barr virus (EBV) appear to increase the risk of relapses in patients with multiple sclerosis (MS), a mouse study suggests. The study, “Epstein Barr virus‐immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice,” was published in the Journal of Medical Virology. EBV, also known as human […]

Anxiety and Depression Linked to RRMS Relapse Risk, Study Finds

Comorbidities such as anxiety and depression are associated with a significantly increased risk of relapse in people with relapsing-remitting multiple sclerosis (RRMS), a clinical trial analysis has found.  Anxiety and abnormal blood lipids (fats) also increased the risk of any RRMS disease activity.  Based on those findings, researchers suggest that the presence of comorbidities (coexisting […]

Switch From Tysabri to Other DMT Raises Relapse Risk, Study Finds

The risk of a relapse is two to three times higher in relapsing-remitting multiple sclerosis (RRMS) patients who switch from Tysabri (natalizumab) to an oral or other injectable disease-modifying therapy after two or more years of its use, than it is in those who stay with Tysabri, a large observational study found. A return of disease activity was […]

Evobrutinib Lowers MS Relapse Rates Over 2 Years of Use, Trial Data Show

Note: This story was updated May 27, 2020, to note a change in the protocol of the EVOLUTION trials, which are now comparing evobrutinib with Aubagio, rather than Avonex, along with updated NCT numbers. The investigational oral medication evobrutinib leads to a sustained reduction in relapse rates in people with relapsing multiple sclerosis (MS), data […]